Successful treatment of HCV-related glomerulonephritis with sofosbuvir and daclatasvir

Nephrology (Carlton). 2018 Apr;23(4):379-380. doi: 10.1111/nep.13087.

Authors

Xiu Xian Chia¹, Svetlana Cherepanoff², Mark Danta³, Tim Furlong¹

Affiliations

¹ Department of Nephrology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.
² Department of Anatomical Pathology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.
³ Department of Gastroenterology and Hepatology, St Vincent's Hospital, Darlinghurst, New South Wales, Australia.

PMID: 29520905
DOI: 10.1111/nep.13087

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antiviral Agents / therapeutic use*
Carbamates
Glomerulonephritis / diagnosis
Glomerulonephritis / drug therapy*
Glomerulonephritis / immunology
Glomerulonephritis / virology
Hepacivirus / drug effects*
Hepacivirus / immunology
Hepacivirus / pathogenicity
Hepatitis C, Chronic / diagnosis
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / immunology
Hepatitis C, Chronic / virology
Host-Pathogen Interactions
Humans
Imidazoles / therapeutic use*
Male
Middle Aged
Pyrrolidines
Sofosbuvir / therapeutic use*
Treatment Outcome
Valine / analogs & derivatives
Viral Load

Substances

Antiviral Agents
Carbamates
Imidazoles
Pyrrolidines
Valine
daclatasvir
Sofosbuvir